CNS Pharmaceuticals Faces Nasdaq Listing Rule Non-Compliance
Ticker: CNSP · Form: 8-K · Filed: 2024-09-18T00:00:00.000Z
Sentiment: neutral
Topics: listing-rules, nasdaq, compliance
Related Tickers: CNSP
TL;DR
Nasdaq says CNS Pharmaceuticals is in danger of being delisted, company is fighting back.
AI Summary
CNS Pharmaceuticals, Inc. received a notification on September 12, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Market. The company is currently evaluating the notification and plans to request a hearing with the Nasdaq Hearings Panel to present its plan to regain compliance.
Why It Matters
Failure to regain compliance could lead to the delisting of CNS Pharmaceuticals' stock from the Nasdaq Capital Market, impacting its liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company has received a notification of non-compliance with Nasdaq listing rules, which could lead to delisting.
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Exchange where shares are listed
- September 12, 2024 (date) — Date of notification
FAQ
What specific Nasdaq listing rule did CNS Pharmaceuticals fail to meet?
The filing states that CNS Pharmaceuticals, Inc. received a notification that it failed to meet a continued listing rule or standard for the Nasdaq Capital Market, but does not specify which rule.
When did CNS Pharmaceuticals receive this notification?
CNS Pharmaceuticals, Inc. received the notification on September 12, 2024.
What is CNS Pharmaceuticals' immediate plan in response to the notification?
The company is evaluating the notification and intends to request a hearing with the Nasdaq Hearings Panel to present its plan to regain compliance.
What is the potential consequence if CNS Pharmaceuticals cannot regain compliance?
If CNS Pharmaceuticals cannot regain compliance with Nasdaq's listing rules, its securities may be delisted from the Nasdaq Capital Market.
Where is CNS Pharmaceuticals, Inc. incorporated and what is its principal executive office?
CNS Pharmaceuticals, Inc. is incorporated in Nevada and its principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.
Filing Stats: 633 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2024-09-18 16:30:08
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
- $1.00 — d not maintained a closing bid price of $1.00 per share (the "Minimum Bid Price Requi
Filing Documents
- cns_8k.htm (8-K) — 27KB
- 0001683168-24-006495.txt ( ) — 200KB
- cnsp-20240912.xsd (EX-101.SCH) — 3KB
- cnsp-20240912_lab.xml (EX-101.LAB) — 33KB
- cnsp-20240912_pre.xml (EX-101.PRE) — 24KB
- cns_8k_htm.xml (XML) — 4KB
01. Notice
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 12, 2024, CNS Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") notifying the Company that for the previous 30 consecutive business days the Company's common stock had not maintained a closing bid price of $1.00 per share (the "Minimum Bid Price Requirement") required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Nasdaq letter does not result in the immediate delisting of the Company's common stock from The Nasdaq Capital Market. Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) because the Company effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. Accordingly, unless the Company timely requests a hearing before a Hearings Panel (the "Panel"), the Company's securities would be subject to suspension/delisting. The Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period if granted by the Panel following the hearing. There can be no assurance that the Panel will grant the Company an additional extension period or that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuti